Effect of RAS Blockers on CKD Progression in Elderly Patients With Non Proteinuric Nephropathies (PROERCAN01)
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This study evaluates the effect of renin-angiotensin blockers on chronic kidney disease
progression in elderly (>65 years old) patients with non-proteinuric nephropathies. Half of
the patients will receive angiotensin converting enzyme inhibitors, while the other half will
not receive them. Renal function, proteinuria and cardiovascular events will be follow up
during a three year period.